These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35710418)

  • 1. Myeloid-related protein 8/14 in plasma and serum in patients with new-onset juvenile idiopathic arthritis in real-world setting in a single center.
    Keskitalo PL; Kangas SM; Sard S; Pokka T; Glumoff V; Kulmala P; Vähäsalo P
    Pediatr Rheumatol Online J; 2022 Jun; 20(1):42. PubMed ID: 35710418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis.
    Holzinger D; Frosch M; Kastrup A; Prince FH; Otten MH; Van Suijlekom-Smit LW; ten Cate R; Hoppenreijs EP; Hansmann S; Moncrieffe H; Ursu S; Wedderburn LR; Roth J; Foell D; Wittkowski H
    Ann Rheum Dis; 2012 Jun; 71(6):974-80. PubMed ID: 22267331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRP8/14 and neutrophil elastase for predicting treatment response and occurrence of flare in patients with juvenile idiopathic arthritis.
    Barendregt AM; Veldkamp SR; Hissink Muller PCE; van de Geer A; Aarts C; van Gulik EC; Schilham MW; Kessel C; Keizer MP; Hemke R; Nassar-Sheikh Rashid A; Dolman KM; Schonenberg-Meinema D; Ten Cate R; van den Berg JM; Maas M; Kuijpers TW
    Rheumatology (Oxford); 2020 Sep; 59(9):2392-2401. PubMed ID: 31904851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis.
    Anink J; Van Suijlekom-Smit LW; Otten MH; Prince FH; van Rossum MA; Dolman KM; Hoppenreijs EP; ten Cate R; Ursu S; Wedderburn LR; Horneff G; Frosch M; Vogl T; Gohar F; Foell D; Roth J; Holzinger D
    Arthritis Res Ther; 2015 Aug; 17(1):200. PubMed ID: 26249667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 protein.
    Moncrieffe H; Ursu S; Holzinger D; Patrick F; Kassoumeri L; Wade A; Roth J; Wedderburn LR
    Rheumatology (Oxford); 2013 Aug; 52(8):1467-76. PubMed ID: 23620557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid related proteins MRP8/MRP14 may predict disease flares in juvenile idiopathic arthritis.
    Schulze zur Wiesch A; Foell D; Frosch M; Vogl T; Sorg C; Roth J
    Clin Exp Rheumatol; 2004; 22(3):368-73. PubMed ID: 15144135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop?
    Foell D; Frosch M; Schulze zur Wiesch A; Vogl T; Sorg C; Roth J
    Ann Rheum Dis; 2004 Feb; 63(2):206-8. PubMed ID: 14722212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Serum Calprotectin in Defining Disease Outcomes in Non-Systemic Juvenile Idiopathic Arthritis: A Pilot Study.
    d'Angelo DM; Attanasi M; Di Donato G; Lapergola G; Flacco M; Chiarelli F; Altobelli E; Breda L
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of MRP8/14 in clinical practice as a predictor of outcome after methotrexate withdrawal in patients with juvenile idiopathic arthritis.
    Sumner EJ; Almeida B; Palman J; Bale P; Heard C; Holzinger D; Roth J; Foell D; Robinson E; Ursu S; Wallace C; Gilmour K; Wedderburn LR; Ralph E
    Clin Rheumatol; 2022 Sep; 41(9):2825-2830. PubMed ID: 35486225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TLR4 endogenous ligand MRP8/14 level in enthesitis-related arthritis and its association with disease activity and TLR4 expression.
    Rahman MT; Myles A; Gaur P; Misra R; Aggarwal A
    Rheumatology (Oxford); 2014 Feb; 53(2):270-4. PubMed ID: 24231443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial.
    Foell D; Wulffraat N; Wedderburn LR; Wittkowski H; Frosch M; Gerss J; Stanevicha V; Mihaylova D; Ferriani V; Tsakalidou FK; Foeldvari I; Cuttica R; Gonzalez B; Ravelli A; Khubchandani R; Oliveira S; Armbrust W; Garay S; Vojinovic J; Norambuena X; Gamir ML; García-Consuegra J; Lepore L; Susic G; Corona F; Dolezalova P; Pistorio A; Martini A; Ruperto N; Roth J;
    JAMA; 2010 Apr; 303(13):1266-73. PubMed ID: 20371785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Serum MRP8/14 in Predicting Response to Methotrexate in Children With Juvenile Idiopathic Arthritis.
    Bagri NK; Karmakar S; Haldar P; Lodha R; Kabra SK
    J Clin Rheumatol; 2021 Dec; 27(8):e336-e341. PubMed ID: 32658390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis.
    Brunner HI; Schulert GS; Sproles A; Thornton S; Cornejo GV; Antón J; Cuttica R; Henrickson M; Foeldvari I; Kingsbury DJ; Askelson M; Liu J; Mukherjee S; Wong RL; Lovell DJ; Martini A; Ruperto N; Grom AA;
    Arthritis Res Ther; 2024 Jun; 26(1):125. PubMed ID: 38918871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis.
    Kane D; Roth J; Frosch M; Vogl T; Bresnihan B; FitzGerald O
    Arthritis Rheum; 2003 Jun; 48(6):1676-85. PubMed ID: 12794836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy.
    Hinze CH; Foell D; Johnson AL; Spalding SJ; Gottlieb BS; Morris PW; Kimura Y; Onel K; Li SC; Grom AA; Taylor J; Brunner HI; Huggins JL; Nocton JJ; Haines KA; Edelheit BS; Shishov M; Jung LK; Williams CB; Tesher MS; Costanzo DM; Zemel LS; Dare JA; Passo MH; Ede KC; Olson JC; Cassidy EA; Griffin TA; Wagner-Weiner L; Weiss JE; Vogler LB; Rouster-Stevens KA; Beukelman T; Cron RQ; Kietz D; Schikler K; Mehta J; Ting TV; Verbsky JW; Eberhard AB; Huang B; Giannini EH; Lovell DJ
    Arthritis Rheumatol; 2019 Mar; 71(3):451-459. PubMed ID: 30225949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid-related Protein 8/14 Levels in Rheumatoid Arthritis: Marker of Disease Activity and Response to Methotrexate.
    Patro PS; Singh A; Misra R; Aggarwal A
    J Rheumatol; 2016 Apr; 43(4):731-7. PubMed ID: 26834220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever.
    Park C; Miranda-Garcia M; Berendes R; Horneff G; Kuemmerle-Deschner J; Ganser G; Huppertz HI; Minden K; Haas JP; Jansson AF; Borte M; Schuetz C; Oommen P; Frosch M; Schlueter B; Richter-Unruh A; Kessel C; Hinze C; Wittkowski H; Roth J; Foell D; Holzinger D
    Rheumatology (Oxford); 2022 Jul; 61(7):3082-3092. PubMed ID: 34559193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid related protein 8 and 14 secretion reflects phagocyte activation and correlates with disease activity in juvenile idiopathic arthritis treated with autologous stem cell transplantation.
    Wulffraat NM; Haas PJ; Frosch M; De Kleer IM; Vogl T; Brinkman DM; Quartier P; Roth J; Kuis W
    Ann Rheum Dis; 2003 Mar; 62(3):236-41. PubMed ID: 12594109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Factors and Biomarkers for the Occurrence of Uveitis in Juvenile Idiopathic Arthritis: Data From the Inception Cohort of Newly Diagnosed Patients With Juvenile Idiopathic Arthritis Study.
    Tappeiner C; Klotsche J; Sengler C; Niewerth M; Liedmann I; Walscheid K; Lavric M; Foell D; Minden K; Heiligenhaus A
    Arthritis Rheumatol; 2018 Oct; 70(10):1685-1694. PubMed ID: 29732713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis.
    Rothmund F; Gerss J; Ruperto N; Däbritz J; Wittkowski H; Frosch M; Wulffraat NM; Wedderburn LR; Holzinger D; Gohar F; Vastert SJ; Brik R; Deslandre CJ; Melo-Gomes JA; Saad Magalhaes C; Barcellona R; Russo R; Gattorno M; Martini A; Roth J; Foell D;
    Arthritis Care Res (Hoboken); 2014 Jun; 66(6):949-55. PubMed ID: 24339418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.